MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s40262-026-01651-3

Медицинская библиотека · Clinical pharmacokinetics · 2026

Vutrisiran-Mediated Knockdown of Transthyretin in Patients with ATTR Amyloidosis.

Fontana Marianna, Algalarrondo Vincent, Garcia-Pavia Pablo, Maurer Mathew S, Gillmore Julian D, Cappelli Francesco, Kolachana Kiranmai, Gao Xiuqing, Jadhav Satyawan, Mehrotra Nitin, Robbie Gabriel, Badri Prajakta

СтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

BACKGROUND AND

OBJECTIVE

We assessed the consistency of serum transthyretin (TTR) knockdown with the RNA interference therapeutic vutrisiran across subpopulations of patients with hereditary TTR amyloidosis (ATTR) with polyneuropathy (ATTRv-PN) in HELIOS-A (NCT03759379) and ATTR with cardiomyopathy (ATTR-CM) in HELIOS-B (NCT04153149).

METHODS

Patients received vutrisiran 25 mg subcutaneously every 3 months (Q3M). Serum TTR was measured during randomized treatment through Month 18 in HELIOS-A (post-dose/peak and pre-dose/trough sampling) and Month 30 in HELIOS-B (trough only, except Week 6). The effects of intrinsic/extrinsic factors on serum TTR knockdown from baseline were assessed. Pharmacokinetic/pharmacodynamic modeling was used to support consistency in TTR knockdown between studies.

RESULTS

Observed median (95% confidence interval [CI]) serum TTR knockdown with vutrisiran was 64.2% (61.6-67.8) at Week 3 (n = 114), with steady-state trough knockdown 86.2% (84.1-92.6) (n = 118) in HELIOS-A, and 69.0% (66.0-72.0) at Week 6 (n = 294), with steady-state trough knockdown 82.5% (80.5-84.9) (n = 307) in HELIOS-B. There were no meaningful differences in serum TTR percent knockdown across subgroups defined by baseline characteristics, including age, sex, ethnicity/race, weight, TTR genotype, N-terminal pro-B-type natriuretic peptide, and serum TTR concentration (both studies), and ATTRwt/ATTRv, disease stage/severity, troponin I, and tafamidis use (HELIOS-B), or anti-drug antibodies. Model-predicted peak serum TTR knockdown in HELIOS-B was sustained and consistent with observed knockdown in HELIOS-A; predicted median (95% CI) reduction at Month 30 was 87.1% (84.8-89.4).

CONCLUSIONS

Vutrisiran led to rapid, sustained, and consistent TTR knockdown in HELIOS-A and HELIOS-B, supporting fixed-dose vutrisiran 25 mg Q3M across patients with ATTRv-PN and ATTR-CM.

Для цитирования: Fontana Marianna, Algalarrondo Vincent, Garcia-Pavia Pablo, Maurer Mathew S, Gillmore Julian D, Cappelli Francesco, Kolachana Kiranmai, Gao Xiuqing, Jadhav Satyawan, Mehrotra Nitin, Robbie Gabriel, Badri Prajakta. Vutrisiran-Mediated Knockdown of Transthyretin in Patients with ATTR Amyloidosis.. Clinical pharmacokinetics. 2026. DOI: 10.1007/s40262-026-01651-3.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.